Published online before print September 24, 2009, doi: 10.1161/CIRCHEARTFAILURE.108.798389
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Articles |
Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Patients With Heart Failure
From the Kerckhoff-Klinik, Department of Cardiology and Cardiosurgery (V.M.), Bad Nauheim, Germany; Klinicki Center Serbia (P.S.), Institut za kardiovaskularne bolest, Belgrad; Medicinski Facultet Uni Novi Sad (S.D.), Institut za kardiovaskularne bolest, Sremska Kamenica; Clinical Centre Bezanijska Kosa, Department of Cardiology (M.K.), Zemum; Dedinje Cardiovascular Institute Milana Tepica 1 (A.N.), Belgrade, Serbia; Stavanger Universitetssykehus Kardiologisk divisjon (K.D.), Stavanger, Norway; Solvay Pharmaceuticals Research Laboratories (H.V., C.B., D.Z., R.N., H.E., C.V., B.H.), Hannover, Germany and Weesp, The Netherlands; and Center for Cardiovascular Research/Department of Pharmacology and Toxicology (M.G., B.H.), Charité, Campus Mitte, Berlin, Germany.
Correspondence to Berthold Hocher, MD, Solvay Pharmaceuticals, Hans Böckler Allee 20, D-30173 Hannover, Germany. E-mail berthold.hocher{at}charite.de
Received June 12, 2008; accepted September 3, 2009.
Background— Blocking the tubuloglomerular feedback mechanism with adenosine A1 receptor antagonists seems to improve diuresis and sodium excretion without compromising the glomerular filtration rate in patients with heart failure. However, the direct cardiac effects of this compound class have not been investigated to date.
Methods and Results— In total, 111 patients (109 men and 2 women) received a 1-hour infusion of 5, 10, and 15 mg SLV320, an adenosine A1 receptor antagonist, placebo, or 40 mg furosemide. Mean age was 57.9 years, mean ejection fraction was 28.1%, 82 patients were of New York Heart Association class II, and 29 patients were of New York Heart Association class III. Hemodynamic parameters (heart rate, blood pressure, pulmonary capillary wedge pressure, mean pulmonary arterial pressure, systemic vascular resistance, right atrial pressure, and cardiac output) were determined. Kidney function was assessed by cystatin C measurements and by analysis of urine output and urine electrolytes. In addition, pharmacokinetics of SLV320 and ex vivo inhibition of adenosine A1 receptor activity were performed. SLV320 was well tolerated, and no serious adverse events were observed. Heart rate, blood pressure, pulmonary capillary wedge pressure, mean pulmonary arterial pressure, right atrial pressure, and cardiac output were not altered by any dose of SLV320. Pulmonary capillary wedge pressure was significantly (P=0.04) decreased by furosemide (–6.2±5.9 mm Hg). Systemic vascular resistance was significantly (P=0.04) increased in the furosemide group (+166.70±261.87 dynes · s–1 · cm–5), whereas all SLV320 groups showed no significant alterations of systemic vascular resistance. Changes from baseline cystatin C plasma concentrations decreased after 10 mg SLV320 (–0.093±0.137 mg/L, P=0.046), whereas furosemide resulted in a significant (P=0.03) increase of cystatin C (+0.052±0.065 mg/L) versus baseline. All values represent mean changes±SD from baseline at 3 hours postdosing: SLV320 (10 and 15 mg) increased significantly sodium excretion and diuresis compared with placebo during the 0- to 6-hour collection period postdosing.
Conclusions— SLV320 infusion shows no immediate effects on cardiac hemodynamics. SLV320 might improve glomerular filtration rate while simultaneously promoting natriuresis and diuresis.
Clinical Trial Registration— clinicaltrials.gov Indentifier: NCT00160134.
Key Words: adenosine A1 antagonist • renal function • congestive heart failure • diuretics
CLINICAL PERSPECTIVE
Related Article
- Adenosine A1 Receptor Antagonists at a Fork in the Road
- Michael M. Givertz
Circ Heart Fail 2009 2: 519-522.[Extract] [Full Text] [PDF]